RecruitingNCT07174388
An External Control Arm Study in Non-Small Cell Lung Cancer
A Prospective Study to Generate Precision External Controls in Advanced or Metastatic Non Small Cell Lung Cancer Patients
Sponsor
N-Power Medicine
Enrollment
650 participants
Start Date
Jan 7, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
A study to create control arms using current and future information in patients with lung cancer.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This observational study is collecting data from real patients with non-small cell lung cancer (NSCLC) who are receiving second- or third-line treatments. It aims to build a dataset to better understand how these patients respond to treatment in everyday clinical practice (not in a controlled trial setting).
**You may be eligible if...**
- You are over 18 years old with confirmed NSCLC
- You are fit enough for further treatment and are receiving or about to start second-line therapy
- You have a life expectancy of more than 3 months and can give informed consent
**You may NOT be eligible if...**
- You cannot give informed consent
- You are currently enrolled in another interventional clinical trial
- Your baseline imaging scans do not meet the protocol's required format
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(8)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07174388
Related Trials
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
NCT0500540346 locations
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533283 locations
CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
NCT074137571 location
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
NCT066944541 location
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
NCT070284898 locations